Literature DB >> 11666295

A Novel Potassium-Binding Hydrolysis Product of Ascidiacyclamide: A Cyclic Octapeptide Isolated from the Ascidian Lissoclinum patella.

Anna L. van Den Brenk1, David P. Fairlie, Lawrence R. Gahan, Graeme R. Hanson, Trevor W. Hambley.   

Abstract

A new octapeptide has been isolated and characterized as its potassium complex from acidic aqueous methanol solutions of ascidiacyclamide, a cyclic peptide isolated from the ascidian Lissoclinum patella. Crystals suitable for X-ray structure determination were orthorhombic, space group P2(1)2(1)2(1), with a = 15.442(3) Å, b = 36.167(1) Å, c = 9.567(3) Å, V = 5343(2) Å(3), Z = 4, and R = 0.069. The structure consists of the macrocyclic cation, three perchlorate anions, and two water molecules. The macrocyclic ring of ascidiacyclamide remains intact, but two oxazoline rings have been opened to form two amino lactones, with the amine protonated. A potassium ion is bound to the N atoms of the thiazole rings (K(1).N(1), 2.47(2) Å; K(1).N(5), 2.50(2) Å) and to the adjacent O (amide) atoms (K(1).O(1), 2.34(1) Å; K(1).O(5), 2.34(1) Å). Two perchlorate anions, located on either side of the plane of the macrocyclic ring, are weakly associated with the potassium cation (K(1).O(10), 2.72(3) Å; K(1).O(16), 2.48(3) Å). This cyclic octapeptide reacts with copper(II) to give a purple solution (lambda(max) 590 nm).

Entities:  

Year:  1996        PMID: 11666295     DOI: 10.1021/ic9504755

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  2 in total

Review 1.  Ribosomal peptide natural products: bridging the ribosomal and nonribosomal worlds.

Authors:  John A McIntosh; Mohamed S Donia; Eric W Schmidt
Journal:  Nat Prod Rep       Date:  2009-04       Impact factor: 13.423

2.  Bistratamides M and N, Oxazole-Thiazole Containing Cyclic Hexapeptides Isolated from Lissoclinum bistratum Interaction of Zinc (II) with Bistratamide K.

Authors:  Carlos Urda; Rogelio Fernández; Jaime Rodríguez; Marta Pérez; Carlos Jiménez; Carmen Cuevas
Journal:  Mar Drugs       Date:  2017-07-01       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.